Print this page
-
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia.
Protocol: 021808Principal Investigator:
- Dale Schaar M.D,Ph.D (Rutgers University)
Applicable Disease Sites: Leukemia, other -
A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy).
Protocol: 111903Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Lymphoid Leukemia -
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP).
Protocol: 111905Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations.
Protocol: 022004Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults.
Protocol: 022101Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia